Never miss the latest news and offers - subscribe now!
As gene therapies move toward commercialization, a robust, scalable and affordable manufacturing process is critical to ensure these novel therapies reach the patient and that a pipeline of clinical assets can be rapidly developed. In this webinar, we will present an end user case study which illustrates how Freeline Therapeutics and Pall Biotech worked together to set up an end-to-end manufacturing process to support Freeline’s pipeline of adeno-associated virus products. Attendees will learn how integrated solutions enable efficient viral vector manufacturing, the tools available to simplify and streamline your process while reducing risk and key lessons learnt around facility set up.
Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook